AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition
AbbVie Inc. has completed an $8.0 billion senior notes offering to partially fund its acquisition of Apogee Therapeutics, Inc. The offering includes various series of notes with different interest rates and maturity dates, increasing AbbVie's total debt to approximately $78.9 billion. The company also reported strong second-quarter 2026 revenues and raised earnings per share, leading to increased price targets from several analysts.
NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE
NINE MASTS CAPITAL Ltd recently acquired a new position of 9,400 shares in Apogee Therapeutics Inc. (NASDAQ:APGE), valued at approximately $1.25 million. This move comes as institutional investors collectively own 79.04% of the company, despite several analysts downgrading APGE to "hold" or "neutral" with a consensus price target of $124.43. The company also reported a quarterly loss of $1.14 per share, missing estimates, and insiders have sold a significant number of shares recently.
Apogee Therapeutics CMO Dambkowski sells $737k in stock
Carl Dambkowski, CMO of Apogee Therapeutics, sold 5,500 shares for $737,934 on August 5, 2026, under a pre-arranged trading plan, while also exercising options to acquire 4,125 shares. This transaction occurred near the stock's 52-week high and after the company's acquisition by AbbVie was approved by shareholders for $10.9 billion. Analysts subsequently downgraded Apogee's stock, though some increased price targets to reflect the acquisition value.
Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal
Apogee Therapeutics, Inc. (NASDAQ: APGE) reported $1.3 billion in cash but an $85.9 million net loss in Q2 2026, primarily due to increased spending on its zumilokibart program. Its directors are set to resign following the closing of the AbbVie acquisition, which will make Apogee an indirect wholly owned subsidiary of AbbVie.
Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE
Alberta Investment Management Corp has acquired a new position in Apogee Therapeutics Inc. (NASDAQ:APGE), purchasing 75,000 shares valued at approximately $9.96 million. Other institutional investors like TD Asset Management Inc., Vanguard Group Inc., and Bank of America Corp DE also increased their stakes in the company. Analysts have issued a consensus "Hold" rating for Apogee Therapeutics, with an average price target of $124.43.
Apogee Therapeutics CMO Dambkowski sells $737k in stock
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 5,500 shares of the company's stock for over $737,000 but also acquired 4,125 shares through stock option exercises. These transactions occurred as the stock traded near its 52-week high, and following the company's acquisition by AbbVie for $10.9 billion.
Liquidity Mapping Around (APGE) Price Events
This article provides a detailed liquidity mapping analysis for Apogee Therapeutics Inc. (NASDAQ: APGE), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines institutional trading strategies including long, momentum breakout, and short positions with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal data and AI-generated signals for support and resistance levels.
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Consensus Recommendation of "Hold" from Analysts
Apogee Therapeutics Inc. (NASDAQ:APGE) has received a consensus "Hold" rating from analysts, with 15 out of 20 firms issuing hold ratings. The average 12-month price target is $124.43, while the stock recently opened at $134.55. The company reported a quarterly loss of $1.14 per share, missing estimates, and saw significant insider selling of approximately $20.3 million worth of shares in the last quarter.
Handelsbanken Fonder AB Has $11.46 Million Stake in Apogee Therapeutics Inc. $APGE
Handelsbanken Fonder AB significantly increased its stake in Apogee Therapeutics Inc. by 309% in Q2, bringing its total holdings to 86,300 shares valued at approximately $11.46 million. Despite institutional interest, Apogee Therapeutics reported a quarterly loss that missed analyst expectations, and company insiders have sold a substantial amount of shares recently. Analysts currently hold a "Hold" consensus rating for the stock, with an average price target of $124.43.
Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research
BTIG Research has downgraded Apogee Therapeutics (NASDAQ:APGE) from a "buy" to a "neutral" rating. This follows a broader trend of analysts issuing "Hold" ratings, with the consensus price target at $121.25, despite the company's shares opening near their 52-week high and reporting a quarterly loss worse than expected. Insider selling of approximately $20.3 million in shares has occurred, though institutional investors and hedge funds maintain a significant stake.
Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options
Fairmount-affiliated entities reported exercising options to acquire 42,208 shares of Apogee Therapeutics (APGE) common stock on August 7, 2026, at strike prices of $17.00 and $43.85 per share. These shares are held indirectly through Fairmount Healthcare Fund II L.P., with Tomas Kiselak and Peter Harwin disclaiming beneficial ownership except for their pecuniary interest. The transaction details were filed in a Form 4 with the SEC.
Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS
Apogee Therapeutics (NASDAQ:APGE) reported a quarterly loss of $2.07 per share, missing analyst expectations by $1.00, as the consensus called for a $1.07 loss. Following the announcement, several analysts downgraded the stock or adjusted their price targets. Insiders have sold approximately $22.0 million worth of stock in the last 90 days, while institutional investors and hedge funds own 79.04% of the company.
Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary
Apogee Therapeutics, Inc. reported a consolidated net loss of $85.9M for Q2 2026 and $160M for the first half of 2026, marking an increase from the previous year, as the company has no product sales. Despite the losses, the company highlighted positive Phase 2 results for zumilokibart, with Phase 3 trials planned for H2 2026 and expansion into ADventure trials with data expected in 2028. Apogee Therapeutics also secured funding and a revenue-share deal to support its pipeline development.
Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates
Apogee Therapeutics announced its second quarter 2026 financial results and provided updates on its corporate and pipeline developments. The company reported a pending acquisition by AbbVie for $135.11 per share, totaling approximately $10.9 billion, and positive 16-week Phase 2 APEX Part B results for zumilokibart, supporting its planned advancement into Phase 3 for moderate-to-severe atopic dermatitis. Apogee also detailed its strategic financing collaboration with Blackstone Life Sciences and pipeline progress for other indications like EoE and asthma.
Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE
Bank of America Corp DE increased its stake in Apogee Therapeutics Inc. (NASDAQ:APGE) by 13.5% in the first quarter, now holding 900,871 shares valued at $75.8 million. Despite this institutional interest, company insiders, including CEO Michael Henderson, sold over 180,000 shares totaling approximately $22 million in the last 90 days. Analyst ratings are mixed with a consensus "Hold" and an average price target of $121.25, while the stock recently traded near its 12-month high.
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares
Carl Dambkowski, an insider at Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares of the company's stock for approximately $737,935. This sale, conducted under a Rule 10b5-1 plan, reduced his ownership by 3.16% to 168,498 shares. The company's stock traded up 0.3% to $134.84, near its 52-week high, while analysts maintain a "Hold" consensus rating with an average price target of $121.25.
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares
Carl Dambkowski, CMO at Apogee Therapeutics, sold 5,500 shares for $737,934 and acquired 4,125 shares via option exercise for $94,297. These transactions occurred under a pre-arranged trading plan, with the stock trading near its 52-week high and appearing overvalued. The company is also in the process of being acquired by AbbVie for approximately $10.9 billion.
Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares
Carl Dambkowski, CMO of Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares for $737,934 under a 10b5-1 plan, while also acquiring 4,125 shares through option exercise. The company is set to be acquired by AbbVie for $10.9 billion, leading to analyst downgrades to "Neutral." These events highlight significant strategic movements and analyst perspectives regarding Apogee Therapeutics.
Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE
Sei Investments Co. significantly increased its stake in Apogee Therapeutics Inc. by 158.5% in the first quarter, bringing its total holdings to 42,203 shares valued at approximately $3.55 million. While institutional ownership of APGE is high at 79.04%, company insiders have sold a substantial amount of shares, totaling $21.25 million over the last 90 days. Analyst sentiment for Apogee Therapeutics is largely cautious, with an average "Hold" rating and a price target below its current trading price, despite the stock recently nearing its 52-week high.
Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options for 4,125 shares at $22.86 per share and simultaneously sold 5,500 shares at $134.17 per share on August 5, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. After the transaction, Dambkowski still holds 110,665 outstanding option shares from an original award of 175,345 shares, which vest monthly through December 2027.
Apogee Therapeutics stock hits all-time high at 134.47 USD
Apogee Therapeutics stock has reached an all-time high of $134.47, reflecting a significant 270% 1-year return and a market cap of $10.08 billion. This surge comes as the company is set to be acquired by AbbVie for $135.11 per share, valuing it at approximately $10.9 billion. Despite the positive momentum, InvestingPro data suggests the stock is overvalued and in overbought territory, prompting some analysts to downgrade their ratings.
Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History
Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications. The article provides current stock performance, key financial metrics, analyst ratings, and a company overview, highlighting its drug candidates like Zumilokibart (APG777) in clinical trials for conditions such as atopic dermatitis and asthma.
AbbVie Plans to raise $8 billion to finance deal with Apogee Therapeutics
AbbVie Inc. plans to raise $8 billion through investment-grade bonds to fund its $10.9 billion acquisition of Apogee Therapeutics Inc. This strategic move aims to expand AbbVie's portfolio of anti-inflammatory drugs, particularly with Apogee's zumilokibart, a potential competitor to Sanofi's Dupixent. The acquisition reflects a continuing trend of major deals within the pharmaceutical sector.
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Capital's Baron Health Care Fund exited its position in Apogee Therapeutics (APGE) after the company announced an agreement to be acquired by AbbVie Inc. for $135.11 per share. The acquisition, representing a 49.5% premium, led to the fund selling its shares. Despite this, the Baron Health Care Fund achieved an 11.99% gain in Q2 2026, outperforming the Russell 3000 Health Care Index.
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
Baron Capital's Baron Health Care Fund exited its position in Apogee Therapeutics (APGE) after the company announced an agreement to be acquired by AbbVie Inc. for $135.11 per share. The acquisition represented a 49.5% premium over the prior day's closing stock price. Apogee Therapeutics, a clinical-stage biotechnology company, was a significant contributor to the fund's favorable stock selection in biotechnology during Q2 2026.
Why (APGE) Price Action Is Critical for Tactical Trading
This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE) for tactical trading, indicating a neutral near and mid-term outlook but a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes that no resistance levels remain above the current price, suggesting significant upside potential.
Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?
Apogee Therapeutics (APGE) has seen significant returns recently, but its valuation checks indicate it is currently expensive, scoring 1 out of 6 on Simply Wall St.'s valuation scale. The company's stock trades at a high price-to-book ratio compared to the biotech industry average, suggesting investors are paying a premium relative to its net assets. The article raises the question of whether the company can execute on its development plans strongly enough to justify its current rich valuation, or if its price will eventually align more closely with the broader biotech sector.
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
AbbVie has slightly cut its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics for $10.9 billion, aimed at strengthening its inflammatory disease treatment pipeline. Despite this adjustment, the company exceeded second-quarter earnings and revenue estimates, driven by robust sales of its immunology drugs Skyrizi and Rinvoq, which helped offset a significant decline in Humira sales. Analysts noted the strong performance of the newer drugs but anticipate some market questioning following the share price increase since the Apogee deal announcement.
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates
AbbVie has slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, despite exceeding second-quarter estimates with strong sales of its immunology drugs Skyrizi and Rinvoq. The acquisition, valued at $10.9 billion, aims to strengthen AbbVie's inflammatory disease treatment pipeline. While the deal will have a minor impact on full-year earnings, the strong performance of existing drugs is largely offsetting this effect.
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Shareholders of Apogee are set to receive $135.11 in cash per share. KSF is scrutinizing whether this price and the process leading to the acquisition adequately value the company and is encouraging affected shareholders to contact them regarding their legal rights.
Apogee Therapeutics, Inc. Revenue Breakdown – BOATS:APGE
This article provides financial information for Apogee Therapeutics, Inc. (APGE). It outlines various financial data including statements, statistics, dividends, earnings, and segments. The content is primarily a data and navigational page from TradingView, focusing on investment tools and market data for APGE.
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
Apogee Therapeutics Inc. (APGE) is outperforming its Medical sector peers this year with a 77.9% gain, significantly higher than the sector's 0.8% average return. The stock holds a Zacks Rank #2 (Buy), and its full-year earnings consensus estimate has increased, indicating stronger analyst sentiment. Another strong performer in the Medical sector is Iovance Biotherapeutics (IOVA), which has returned 79.5% year-to-date.
APGE|Apogee Therapeutics Inc|Price:134.310|Chg%:+0.030
This article provides a detailed financial overview of Apogee Therapeutics Inc (APGE), presenting its latest market data, earnings information, and key financial statements. It includes quarterly and annual data for EPS, Net Profit, Balance Sheet particulars like assets and liabilities, and Cash Flow metrics. The report also addresses frequently asked questions concerning the company's financial performance up to FY2025.
Apogee Therapeutics Inc (APGE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Apogee Therapeutics Inc (APGE), detailing its support, resistance, indicators, and moving averages. According to TradingKey, the overall technical signal for APGE is Neutral, with specific indicators showing mixed signals (e.g., RSI and Williams %R are Overbought, while TRIX is a Sell signal). Moving averages, however, predominantly show buy signals across MA5 to MA200.
Apogee Therapeutics Inc (APGE) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Apogee Therapeutics Inc (APGE), focusing on its PE, PB, and fair value. It displays current market data including the stock price, daily change, market capitalization, and a placeholder for P/E TTM, suggesting that detailed financial analysis is available through the platform. The content primarily serves as a gateway to more in-depth financial information on TradingKey.
Apogee Therapeutics Inc (APGE) Institutional Confidence
This article from TradingKey provides an overview of Apogee Therapeutics Inc.'s (APGE) institutional confidence, detailing major institutional shareholders and their recent activity. Key investors like T. Rowe Price Investment Management, Inc., VR Adviser, LLC, and Fidelity Management & Research Company LLC are listed along with their shareholdings and percentage changes. The data highlights institutional involvement and recent shifts in investment in Apogee Therapeutics.
Apogee Therapeutics Inc (APGE) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Apogee Therapeutics Inc (APGE), detailing its volatility, financial risk, and investment risk metrics. It includes data on beta, Value at Risk (VaR), maximum drawdown, volatility, return statistics, Sharpe ratio, and liquidity measures over various timeframes. The information is presented to help investors evaluate the stock's risk profile.
Apogee Therapeutics Inc (APGE) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Apogee Therapeutics Inc (APGE), highlighting current analyst ratings, target prices, and historical and projected EPS. Based on 15 analysts, the stock currently holds a "Hold" rating with an expected upside space of -2.75%. The article also includes a peer comparison and addresses frequently asked questions regarding past and future EPS performance.
Apogee Therapeutics Inc (APGE) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Apogee Therapeutics Inc (APGE), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types and a historical overview of institutional shareholding, including the number of institutions, shares held, and changes over recent quarters. The data indicates significant institutional involvement and changes in their holdings over time, along with related ETFs.
Apogee Therapeutics Inc (APGE) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial analysis of Apogee Therapeutics Inc (APGE), focusing on its profitability and balance sheet. It presents key financial data such as its market capitalization and current stock price. The content is primarily a placeholder for a detailed financial report that is mentioned in the overview.
Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Apogee Therapeutics Inc (APGE) for transactions that occurred on July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article provides the company's stock ticker (APGE) and mentions a slight percentage change in its value.
Form 4 Apogee Therapeutics Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Apogee Therapeutics Inc dated July 24. Form 4s disclose changes in ownership of company stock by insiders. The article itself is very brief and primarily serves as a placeholder for this financial disclosure.
Apogee Therapeutics (APGE) CFO makes bona fide gift of 15,000 shares
Apogee Therapeutics' Chief Financial Officer, Jane Henderson, reported a bona fide gift of 15,000 shares of common stock to a donor-advised fund. This transaction was not executed under a Rule 10b5-1 plan, and following the transfer, Henderson directly holds 158,371 shares of APGE. The gift is valued at $0.00 per share as it was a transfer, not a sale.
Understanding Momentum Shifts in (APGE)
This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE), noting neutral near and mid-term readings but a positive long-term bias. It highlights the absence of resistance levels above the current price, suggesting upside potential. The piece also details AI-generated institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, alongside multi-timeframe signal analysis for support and resistance levels.
Apogee Therapeutics stock hits all-time high at 134.34 USD
Apogee Therapeutics stock reached an all-time high of $134.34 USD, marking a significant milestone with a 243% increase over the past year and a market capitalization of $10.05 billion. The company is set to be acquired by AbbVie for $135.11 per share, following advancements in its lead program zumilokibart, which is progressing to Phase III trials. Analysts have downgraded the stock to Neutral, citing the acquisition price as fair, while InvestingPro indicates the stock is currently overvalued.
Apogee Therapeutics (APGE) Proxy filing Summary
This article summarizes the proxy filing for Apogee Therapeutics (APGE), detailing the upcoming annual meeting on June 9, 2026. Key agenda items include the election of three Class III directors, ratification of Ernst & Young LLP as the independent auditor, and an advisory vote on executive compensation. The company's board structure, corporate governance, and voting eligibility are also outlined, alongside a disclaimer about forward-looking statements.
Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com
This article reports on a Form 4 filing for Apogee Therapeutics Inc. for July 16, as published by Investing.com. It is a brief announcement without further details regarding the contents of the filing. The article indicates the stock symbol APGE.
Form 4 Apogee Therapeutics Inc For: 16 July By Investing.com
This Investing.com article reports on a Form 4 filing for Apogee Therapeutics Inc. dated July 16. It includes stock market data for various indices, commodities, bonds, and individual shares, alongside popular articles and market movers. The article is brief, primarily serving as a notification of the SEC filing.
Apogee Therapeutics (APGE) CMO donates 8,000 shares to donor advised fund
Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, reported a gift of 8,000 shares of common stock on July 14, 2026. The shares were transferred to a donor advised fund as a non-market disposition at $0.00 per share. Following this transaction, Dambkowski directly holds 169,873 shares of Apogee common stock.
